Prices delayed ≤15 min
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care product
Frequently Asked Questions about JNJ
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson is a global leader in the healthcare sector, focusing on researching, developing, manufacturing, and selling a wide range of products. They operate primarily in the drug manufacturing industry, having strategically separated their Consumer Health business into Kenvue Inc. in 2023 to concentrate on higher-growth segments.
Is JNJ stock a good investment in 2026?
Considering Johnson & Johnson's revenue growth of 6.0% and a robust market capitalization of $523.80 billion, the stock may present a balanced investment opportunity. However, investors should also consider the absence of a P/E ratio and EPS data, which complicates direct valuation comparisons.
What is Johnson & Johnson's market capitalisation and stock price?
As of now, Johnson & Johnson's stock price is $217.41, with a market capitalization of approximately $523.80 billion. This positions the company well within the healthcare sector, especially when considering its 52-week high of $220.11.
Does JNJ pay dividends to shareholders?
Currently, Johnson & Johnson does not pay dividends to its shareholders. Instead, the company is focused on reinvesting its profits, which includes a substantial free cash flow of $19.70 billion, to drive growth in its innovation-driven segments.
How profitable is Johnson & Johnson?
Johnson & Johnson boasts a net income of $26.80 billion, resulting in a net margin of 28.5%, which indicates strong profitability. However, specific ROE data is not available, yet the company's free cash flow further highlights its financial strength.
What is JNJ's P/E ratio and is the stock overvalued?
Johnson & Johnson currently has a P/E ratio that is not applicable, as EPS data is not available. This lack of data makes it challenging to assess whether the stock is overvalued compared to its peers in the drug manufacturing sector.
How much debt does Johnson & Johnson have?
Johnson & Johnson's debt-to-equity ratio is not available, indicating a potentially favorable balance sheet. With a current ratio of 1.03 and a strong free cash flow of $19.70 billion, the company appears to maintain a healthy cash position.
What is JNJ's 52-week trading range?
The 52-week trading range for Johnson & Johnson is between $141.50 and $220.11. Currently, the stock price sits at $217.41, which is close to its 52-week high, and above its 50-day moving average of $204.53.
Is JNJ a growth stock or value stock?
Johnson & Johnson exhibits characteristics of a growth stock, with a revenue growth rate of 6.0%. However, without available EPS growth and P/E ratio data, it is difficult to fully categorize it within the growth or value stock spectrum.
What are the main risks of investing in JNJ?
Investing in Johnson & Johnson carries risks such as its low beta of 0.33, which indicates lower volatility but may also suggest less responsiveness to market movements. Additionally, the separation of its Consumer Health business introduces competitive risks in the healthcare sector.